董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Annick Schwebig | 女 | Director | 69 | 4.30万 | 未持股 | 2020-07-06 |
| Chris Buyse | 男 | Director | 55 | 5.40万 | 未持股 | 2020-07-06 |
| Frederic Cren | 男 | Chief Executive Officer and Chairman of the Board of Director | 54 | 37.36万 | 未持股 | 2020-07-06 |
| Pierre Broqua | 男 | Deputy Chief Executive Officer, Chief Scientific Officer and Director | 58 | 26.24万 | 未持股 | 2020-07-06 |
| Heinz Maeusli | 男 | Director | 57 | 2.30万 | 未持股 | 2020-07-06 |
| Nawal Ouzren | 女 | Director | 42 | 2.00万 | 未持股 | 2020-07-06 |
| Lucy Lu | 女 | Director | 46 | 3.10万 | 未持股 | 2020-07-06 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Frederic Cren | 男 | Chief Executive Officer and Chairman of the Board of Director | 54 | 37.36万 | 未持股 | 2020-07-06 |
| Pierre Broqua | 男 | Deputy Chief Executive Officer, Chief Scientific Officer and Director | 58 | 26.24万 | 未持股 | 2020-07-06 |
| Jean Volatier | 男 | Chief Financial Officer | 56 | 未披露 | 未持股 | 2020-07-06 |
| Marie Paule Richard | 女 | Chief Medical Officer | 66 | 未披露 | 未持股 | 2020-07-06 |
董事简历
中英对照 | 中文 | 英文- Annick Schwebig
-
Annick schwebig，2011年10月28日起担任董事会成员。2000年她创立Actelion法国子公司，并担任总经理。Actelion是一家生物制药公司，专注于为未满足的医疗需求服务的创新治疗。2000年起，她也是LEEM法国制药工业协会生物技术董事长，负责协调细胞疗法和纳米医学的研究，以及健康产业（ARIIS）的研究和创新秘书长。她是巴黎医科大学的博士生。从1983到2000年，Schwebig女士还曾在生物制药公司Bristol-Myers Squibb担任高级经理17年。
Annick Schwebig has served as a member of our board of directors since February 2017. In 2000 she founded Actelion Pharmaceuticals France SAS, a pharmaceuticals company specializing in developing drugs for orphan diseases, and was its Chairman and Chief Executive Officer from 2000 to 2015. Ms. Schwebig has held senior positions in the pharmaceutical industry, including Vice President Medical Affairs France and Vice President Research and Development Europe at Bristol-Myers Squibb, a global biopharmaceutical company, from 1983 to 2000. Ms. Schwebig has been a member of the board of directors of Cellectis SA, a biotechnology company, since 2011. Ms. Schwebig is a graduate of the Paris Faculty of Medicine. - Annick schwebig，2011年10月28日起担任董事会成员。2000年她创立Actelion法国子公司，并担任总经理。Actelion是一家生物制药公司，专注于为未满足的医疗需求服务的创新治疗。2000年起，她也是LEEM法国制药工业协会生物技术董事长，负责协调细胞疗法和纳米医学的研究，以及健康产业（ARIIS）的研究和创新秘书长。她是巴黎医科大学的博士生。从1983到2000年，Schwebig女士还曾在生物制药公司Bristol-Myers Squibb担任高级经理17年。
- Annick Schwebig has served as a member of our board of directors since February 2017. In 2000 she founded Actelion Pharmaceuticals France SAS, a pharmaceuticals company specializing in developing drugs for orphan diseases, and was its Chairman and Chief Executive Officer from 2000 to 2015. Ms. Schwebig has held senior positions in the pharmaceutical industry, including Vice President Medical Affairs France and Vice President Research and Development Europe at Bristol-Myers Squibb, a global biopharmaceutical company, from 1983 to 2000. Ms. Schwebig has been a member of the board of directors of Cellectis SA, a biotechnology company, since 2011. Ms. Schwebig is a graduate of the Paris Faculty of Medicine.
- Chris Buyse
-
Chris Buyse，他是Pienter-Jan BVBA的常驻代表。他曾一直担任我们的董事会成员（2008年以来）。他是Life Sciences Research Partners VZW（一个非盈利组织，支持和投资于生命科学创新公司）的现任董事总经理。他也曾创立Fund+NV/SA（基金将投资于比利时生物技术公司）。从2006年8月到2014年6月，他曾担任ThromboGenics公司（一个领先的生物技术公司，在纽约证交所-泛欧交易所上市）的首席财务官兼董事会成员。加入ThromboGenics公司之前，他曾担任CropDesign公司（比利时生物科技公司）的首席财务官，在那里他曾协调2006年7月公司被BASF公司收购。加入CropDesign公司之前，他曾担任WorldCom/MCI Belux公司（世界上最大的电信公司之一的欧洲子公司）的财务经理，也曾担任Keyware Technologies公司的首席财务官兼临时首席执行官。他持有the University of Antwerp的应用经济科学硕士学位，以及Vlerick School of Management（位于根特）的工商管理硕士学位。他目前以他自己的名义或作为管理公司的常驻代表，担任董事会成员，任职于以下公开和私人控股公司：Bone Therapeutics公司、Orgenesis公司、Iteos公司、Bioxodes公司、Bio Incubator公司、Immo David公司、Pinnacle Investments公司、CreaBuild 公司、Sofia BVBA公司、Pienter-Jan BVBA公司、Life Sciences Research Partners VZW （公司的股东）、Keyware Technologies公司。
Chris Buyse has served as a member of our board of directors since February 2017. Chris Buyse is currently the managing partner of Fund+, which is a life sciences investment fund that he co-founded in 2015. Previously, Mr. Buyse was Chief Financial Officer at ThromboGenics NV, a public biotechnology company, from 2006 to 2014. He was previously Chief Financial Officer of CropDesign N.V, a Belgian biotechnology company. Before this, he was Finance Director of WorldCom/MCI Belgium-Luxembourg, a telecommunications company, was Chief Financial Officer and interim Chief Executive Officer of Keyware Technologies N.V., an IT company, and held several financial positions at Suez Lyonnaise des Eaux and Unilever. He is currently serving as an independent director of Celyad SA, a public biotechnology company, as well as Bioxodes SA, a biotechnology company. Mr. Buyse holds a master's degree in applied economic sciences from the University of Antwerp and a master's degree in business administration from the Vlerick School of Management in Ghent. - Chris Buyse，他是Pienter-Jan BVBA的常驻代表。他曾一直担任我们的董事会成员（2008年以来）。他是Life Sciences Research Partners VZW（一个非盈利组织，支持和投资于生命科学创新公司）的现任董事总经理。他也曾创立Fund+NV/SA（基金将投资于比利时生物技术公司）。从2006年8月到2014年6月，他曾担任ThromboGenics公司（一个领先的生物技术公司，在纽约证交所-泛欧交易所上市）的首席财务官兼董事会成员。加入ThromboGenics公司之前，他曾担任CropDesign公司（比利时生物科技公司）的首席财务官，在那里他曾协调2006年7月公司被BASF公司收购。加入CropDesign公司之前，他曾担任WorldCom/MCI Belux公司（世界上最大的电信公司之一的欧洲子公司）的财务经理，也曾担任Keyware Technologies公司的首席财务官兼临时首席执行官。他持有the University of Antwerp的应用经济科学硕士学位，以及Vlerick School of Management（位于根特）的工商管理硕士学位。他目前以他自己的名义或作为管理公司的常驻代表，担任董事会成员，任职于以下公开和私人控股公司：Bone Therapeutics公司、Orgenesis公司、Iteos公司、Bioxodes公司、Bio Incubator公司、Immo David公司、Pinnacle Investments公司、CreaBuild 公司、Sofia BVBA公司、Pienter-Jan BVBA公司、Life Sciences Research Partners VZW （公司的股东）、Keyware Technologies公司。
- Chris Buyse has served as a member of our board of directors since February 2017. Chris Buyse is currently the managing partner of Fund+, which is a life sciences investment fund that he co-founded in 2015. Previously, Mr. Buyse was Chief Financial Officer at ThromboGenics NV, a public biotechnology company, from 2006 to 2014. He was previously Chief Financial Officer of CropDesign N.V, a Belgian biotechnology company. Before this, he was Finance Director of WorldCom/MCI Belgium-Luxembourg, a telecommunications company, was Chief Financial Officer and interim Chief Executive Officer of Keyware Technologies N.V., an IT company, and held several financial positions at Suez Lyonnaise des Eaux and Unilever. He is currently serving as an independent director of Celyad SA, a public biotechnology company, as well as Bioxodes SA, a biotechnology company. Mr. Buyse holds a master's degree in applied economic sciences from the University of Antwerp and a master's degree in business administration from the Vlerick School of Management in Ghent.
- Frederic Cren
-
Frederic Cren自2011年共同创立Inventiva以来一直担任我们的首席执行官，自2016年5月以来一直担任我们的董事会主席。此前，他曾于2010年至2012年担任制药公司雅培公司的研究总经理。在加入Abbott之前，Cren先生在Solvay Pharmaceuticals（一家制药公司）和Laboratoires Fournier SA（一家制药公司）担任过多个职位，直到该公司于2005年被Solvay收购。在Laboratories Fournier的职位包括:战略营销副总裁和美国运营副总裁，以及担任执行委员会成员。Solvay的职位包括:业务战略和投资组合主管和研究部高级副总裁，以及担任执行委员会成员。他的职业生涯始于任职Boston Consulting Group，在那里他曾任职（从1993年到2002年）。他在INSEAD获得工商管理硕士学位，在Johns Hopkins University获得国际关系硕士学位，在Paris IX Dauphine University获得经济学学士学位。
Frederic Cren has served as our Chief Executive Officer since co-founding Inventiva in 2011 and as the chairman of our board of directors since May 2016. Previously, he served as the General Manager, Research of Abbott Laboratories, a pharmaceutical company, from 2010 until 2012. Prior to Abbott, Mr. Cren held a number of roles at Solvay Pharmaceuticals, a pharmaceutical company, and at Laboratoires Fournier SA, a pharmaceutical company, prior to its acquisition by Solvay in 2005. Positions at Laboratories Fournier included: Vice-President Strategic Marketing and Vice-President U.S. Operations, as well as serving as a member of the Executive Committee. Positions at Solvay included: Head of Business Strategy and Portfolio and Senior Vice-President of the Research Division, as well as serving as a member of the Executive Committee. Mr. Cren began his career with Boston Consulting Group, where he worked from 1993 to 2002. He received a master's degree in business administration from INSEAD, a master's degree in international relations from Johns Hopkins University and a bachelor's degree in economics from Paris IX Dauphine University. - Frederic Cren自2011年共同创立Inventiva以来一直担任我们的首席执行官，自2016年5月以来一直担任我们的董事会主席。此前，他曾于2010年至2012年担任制药公司雅培公司的研究总经理。在加入Abbott之前，Cren先生在Solvay Pharmaceuticals（一家制药公司）和Laboratoires Fournier SA（一家制药公司）担任过多个职位，直到该公司于2005年被Solvay收购。在Laboratories Fournier的职位包括:战略营销副总裁和美国运营副总裁，以及担任执行委员会成员。Solvay的职位包括:业务战略和投资组合主管和研究部高级副总裁，以及担任执行委员会成员。他的职业生涯始于任职Boston Consulting Group，在那里他曾任职（从1993年到2002年）。他在INSEAD获得工商管理硕士学位，在Johns Hopkins University获得国际关系硕士学位，在Paris IX Dauphine University获得经济学学士学位。
- Frederic Cren has served as our Chief Executive Officer since co-founding Inventiva in 2011 and as the chairman of our board of directors since May 2016. Previously, he served as the General Manager, Research of Abbott Laboratories, a pharmaceutical company, from 2010 until 2012. Prior to Abbott, Mr. Cren held a number of roles at Solvay Pharmaceuticals, a pharmaceutical company, and at Laboratoires Fournier SA, a pharmaceutical company, prior to its acquisition by Solvay in 2005. Positions at Laboratories Fournier included: Vice-President Strategic Marketing and Vice-President U.S. Operations, as well as serving as a member of the Executive Committee. Positions at Solvay included: Head of Business Strategy and Portfolio and Senior Vice-President of the Research Division, as well as serving as a member of the Executive Committee. Mr. Cren began his career with Boston Consulting Group, where he worked from 1993 to 2002. He received a master's degree in business administration from INSEAD, a master's degree in international relations from Johns Hopkins University and a bachelor's degree in economics from Paris IX Dauphine University.
- Pierre Broqua
-
Pierre Broqua自2011年共同创立Inventiva以来一直担任我们的首席科学官，并自2016年5月以来担任我们的副首席执行官兼董事会成员。此前，Broqua博士从2010年到2012年担任雅培公司的研究主管，从2007年到2010年担任Solvay Pharmaceuticals的神经科学主管。加入Solvay之前，Broqua从2002年到2005年担任Laboratoires Fournier SA研究项目主管。他在University of Paris Descartes获得药理学哲学博士学位，在Université；Pierre et Marie Curie，Paris获得化学与生物化学硕士学位。
Pierre Broqua has served as our Chief Scientific Officer since co-founding Inventiva in 2011 and as our Deputy Chief Executive Officer and a member of our board of directors since May 2016. Previously, Dr. Broqua served as a Head of Research for Abbott Laboratories from 2010 until 2012 and as Head of Neuroscience for Solvay Pharmaceuticals from 2007 to 2010. Prior to Solvay, Dr. Broqua was the Director of Research Project for Laboratoires Fournier SA from 2002 to 2005. He has a doctor of philosophy degree in pharmacology from the University of Paris Descartes and a master's degree in chemistry and biochemistry from Université Pierre et Marie Curie, Paris. - Pierre Broqua自2011年共同创立Inventiva以来一直担任我们的首席科学官，并自2016年5月以来担任我们的副首席执行官兼董事会成员。此前，Broqua博士从2010年到2012年担任雅培公司的研究主管，从2007年到2010年担任Solvay Pharmaceuticals的神经科学主管。加入Solvay之前，Broqua从2002年到2005年担任Laboratoires Fournier SA研究项目主管。他在University of Paris Descartes获得药理学哲学博士学位，在Université；Pierre et Marie Curie，Paris获得化学与生物化学硕士学位。
- Pierre Broqua has served as our Chief Scientific Officer since co-founding Inventiva in 2011 and as our Deputy Chief Executive Officer and a member of our board of directors since May 2016. Previously, Dr. Broqua served as a Head of Research for Abbott Laboratories from 2010 until 2012 and as Head of Neuroscience for Solvay Pharmaceuticals from 2007 to 2010. Prior to Solvay, Dr. Broqua was the Director of Research Project for Laboratoires Fournier SA from 2002 to 2005. He has a doctor of philosophy degree in pharmacology from the University of Paris Descartes and a master's degree in chemistry and biochemistry from Université Pierre et Marie Curie, Paris.
- Heinz Maeusli
-
Heinz Maeusli自2019年5月以来一直担任我们的董事会成员。Maeusli先生自2019年11月起担任Progenics Pharmaceuticals（一家生物制药公司）的董事会成员，在那里他担任审计委员会主席。在加入董事会之前，他于2003年至2018年7月担任专注于核医学领域的制药集团Advanced Accelerator Applications AAA的首席财务官，并于2018年1月参与将AAA出售给全球梦百合公司诺华（Novartis）。Maeusli先生拥有纽约哥伦比亚大学（Columbia University）工商管理硕士学位和圣加仑大学（University of St.Gallen）经济学学位。
Heinz Maeusli has served as a member of our board of directors since May 2019. Since November 2019 Mr. Maeusli has served on the board of directors of Progenics Pharmaceuticals, a biopharmaceutical company, where he is the chairman of the audit committee. Prior to joining our board, he served as the Chief Financial Officer of Advanced Accelerator Applications AAA, a pharmaceutical group specializing in the field of nuclear medicine, from 2003 to July 2018 where he was involved with the sale of AAA to Novartis, a global healthcare company, in January 2018. Mr. Maeusli has an MBA from Columbia University in New York and a degree in Economics from the University of St. Gallen. - Heinz Maeusli自2019年5月以来一直担任我们的董事会成员。Maeusli先生自2019年11月起担任Progenics Pharmaceuticals（一家生物制药公司）的董事会成员，在那里他担任审计委员会主席。在加入董事会之前，他于2003年至2018年7月担任专注于核医学领域的制药集团Advanced Accelerator Applications AAA的首席财务官，并于2018年1月参与将AAA出售给全球梦百合公司诺华（Novartis）。Maeusli先生拥有纽约哥伦比亚大学（Columbia University）工商管理硕士学位和圣加仑大学（University of St.Gallen）经济学学位。
- Heinz Maeusli has served as a member of our board of directors since May 2019. Since November 2019 Mr. Maeusli has served on the board of directors of Progenics Pharmaceuticals, a biopharmaceutical company, where he is the chairman of the audit committee. Prior to joining our board, he served as the Chief Financial Officer of Advanced Accelerator Applications AAA, a pharmaceutical group specializing in the field of nuclear medicine, from 2003 to July 2018 where he was involved with the sale of AAA to Novartis, a global healthcare company, in January 2018. Mr. Maeusli has an MBA from Columbia University in New York and a degree in Economics from the University of St. Gallen.
- Nawal Ouzren
-
Nawal Ouzren自2019年5月以来一直担任我们的董事会成员。自2017年以来，Ouzren女士一直担任生物制药公司Sensorion的首席执行官兼董事会成员。在加入Sensorion之前，她曾于2016年6月至2017年4月担任生物制药公司Shire plc的全球遗传病专营权负责人。任职Shire公司之前，Ouzren女士曾担任Baxalta公司的多种职务（2014年至2016年6月Baxalta公司被Shire公司收购）。Ouzren女士持有德国柏林工业大学（Technical University of Berlin，Germany）的化学工程硕士学位，以及法国the Universit&233；de Technologie de Compi&232；gne的化学工程理学硕士学位。
Nawal Ouzren has served as a member of our board of directors since May 2019. Since 2017 Ms. Ouzren has served as the Chief Executive Officer and a member of the Board of Directors of Sensorion, a biopharmaceutical company. Prior to Sensorion, she served as the head of the Global Genetic Diseases Franchise at Shire plc, a biopharmaceutical company, from June 2016 to April 2017. Prior to Shire, Ms. Ouzren held various positions at Baxalta from 2014 to June 2016 when Baxalta was acquired by Shire. Ms. Ouzren holds a Master's degree in Chemical Engineering from the Technical University of Berlin, Germany and a Master of Science in Chemical Engineering from the Université de Technologie de Compiègne, France. - Nawal Ouzren自2019年5月以来一直担任我们的董事会成员。自2017年以来，Ouzren女士一直担任生物制药公司Sensorion的首席执行官兼董事会成员。在加入Sensorion之前，她曾于2016年6月至2017年4月担任生物制药公司Shire plc的全球遗传病专营权负责人。任职Shire公司之前，Ouzren女士曾担任Baxalta公司的多种职务（2014年至2016年6月Baxalta公司被Shire公司收购）。Ouzren女士持有德国柏林工业大学（Technical University of Berlin，Germany）的化学工程硕士学位，以及法国the Universit&233；de Technologie de Compi&232；gne的化学工程理学硕士学位。
- Nawal Ouzren has served as a member of our board of directors since May 2019. Since 2017 Ms. Ouzren has served as the Chief Executive Officer and a member of the Board of Directors of Sensorion, a biopharmaceutical company. Prior to Sensorion, she served as the head of the Global Genetic Diseases Franchise at Shire plc, a biopharmaceutical company, from June 2016 to April 2017. Prior to Shire, Ms. Ouzren held various positions at Baxalta from 2014 to June 2016 when Baxalta was acquired by Shire. Ms. Ouzren holds a Master's degree in Chemical Engineering from the Technical University of Berlin, Germany and a Master of Science in Chemical Engineering from the Université de Technologie de Compiègne, France.
- Lucy Lu
-
Lucy Lu， 她是医学博士，曾担任执行副总裁和首席财务官（自2012年2月22日以来）。她有在医疗保健行业超过10年的经验。从2007年2月到2012年1月，她担任Citigroup Investment Research高级生物技术股票分析师。从2004年到加入花旗集团，她一直任职First Albany Capital，并于2004年4月担任副总裁，于2006年2月成为公司的负责人。她持有纽约大学医学院的医学博士学位，纽约大学医学院的的硕士学位，纽约大学斯特恩商学院的硕士学位。她获得Tennessee大学艺术和科学学院的学士学位。
Lucy Lu,has served as a director of the Company since May 2021 and previously from October 2016 to March 2019. Since April 2022, Dr. Lu has served as Chief Operations Officer of Innovative Cellular Therapeutics, Inc., a company focused on developing cell therapy for solid tumors. Since November 2022, Dr. Lu has served as a director of Inventiva S.A., a clinical stage biopharmaceutical company. From February 2015 to March 2022, Dr. Lu was President, Chief Executive Officer and a director of Avenue Therapeutics, Inc., a company focused on pharmaceutical therapies Veru Inc. ed in the acute care setting. From February 2012 to June 2017, Dr. Lu was the Executive Vice President and Chief Financial Officer of Fortress Biotech, Inc. Prior to working in the biotech industry, Dr. Lu had 10 years of experience in healthcare-related equity research and investment banking. From February 2007 to January 2012, Dr. Lu was a senior biotechnology equity analyst with Citigroup Investment Research. From 2004 until joining Citigroup, she was with First Albany Capital, serving as Vice President from April 2004 until becoming a Principal of First Albany Capital in February 2006. Dr. Lu obtained her M.D. from the New York University School of Medicine and her M.B.A. from the Leonard N. Stern School of Business at New York University. Dr. Lu obtained a B.A. from the University of Tennessee's College of Arts and Science. - Lucy Lu， 她是医学博士，曾担任执行副总裁和首席财务官（自2012年2月22日以来）。她有在医疗保健行业超过10年的经验。从2007年2月到2012年1月，她担任Citigroup Investment Research高级生物技术股票分析师。从2004年到加入花旗集团，她一直任职First Albany Capital，并于2004年4月担任副总裁，于2006年2月成为公司的负责人。她持有纽约大学医学院的医学博士学位，纽约大学医学院的的硕士学位，纽约大学斯特恩商学院的硕士学位。她获得Tennessee大学艺术和科学学院的学士学位。
- Lucy Lu,has served as a director of the Company since May 2021 and previously from October 2016 to March 2019. Since April 2022, Dr. Lu has served as Chief Operations Officer of Innovative Cellular Therapeutics, Inc., a company focused on developing cell therapy for solid tumors. Since November 2022, Dr. Lu has served as a director of Inventiva S.A., a clinical stage biopharmaceutical company. From February 2015 to March 2022, Dr. Lu was President, Chief Executive Officer and a director of Avenue Therapeutics, Inc., a company focused on pharmaceutical therapies Veru Inc. ed in the acute care setting. From February 2012 to June 2017, Dr. Lu was the Executive Vice President and Chief Financial Officer of Fortress Biotech, Inc. Prior to working in the biotech industry, Dr. Lu had 10 years of experience in healthcare-related equity research and investment banking. From February 2007 to January 2012, Dr. Lu was a senior biotechnology equity analyst with Citigroup Investment Research. From 2004 until joining Citigroup, she was with First Albany Capital, serving as Vice President from April 2004 until becoming a Principal of First Albany Capital in February 2006. Dr. Lu obtained her M.D. from the New York University School of Medicine and her M.B.A. from the Leonard N. Stern School of Business at New York University. Dr. Lu obtained a B.A. from the University of Tennessee's College of Arts and Science.
高管简历
中英对照 | 中文 | 英文- Frederic Cren
Frederic Cren自2011年共同创立Inventiva以来一直担任我们的首席执行官，自2016年5月以来一直担任我们的董事会主席。此前，他曾于2010年至2012年担任制药公司雅培公司的研究总经理。在加入Abbott之前，Cren先生在Solvay Pharmaceuticals（一家制药公司）和Laboratoires Fournier SA（一家制药公司）担任过多个职位，直到该公司于2005年被Solvay收购。在Laboratories Fournier的职位包括:战略营销副总裁和美国运营副总裁，以及担任执行委员会成员。Solvay的职位包括:业务战略和投资组合主管和研究部高级副总裁，以及担任执行委员会成员。他的职业生涯始于任职Boston Consulting Group，在那里他曾任职（从1993年到2002年）。他在INSEAD获得工商管理硕士学位，在Johns Hopkins University获得国际关系硕士学位，在Paris IX Dauphine University获得经济学学士学位。
Frederic Cren has served as our Chief Executive Officer since co-founding Inventiva in 2011 and as the chairman of our board of directors since May 2016. Previously, he served as the General Manager, Research of Abbott Laboratories, a pharmaceutical company, from 2010 until 2012. Prior to Abbott, Mr. Cren held a number of roles at Solvay Pharmaceuticals, a pharmaceutical company, and at Laboratoires Fournier SA, a pharmaceutical company, prior to its acquisition by Solvay in 2005. Positions at Laboratories Fournier included: Vice-President Strategic Marketing and Vice-President U.S. Operations, as well as serving as a member of the Executive Committee. Positions at Solvay included: Head of Business Strategy and Portfolio and Senior Vice-President of the Research Division, as well as serving as a member of the Executive Committee. Mr. Cren began his career with Boston Consulting Group, where he worked from 1993 to 2002. He received a master's degree in business administration from INSEAD, a master's degree in international relations from Johns Hopkins University and a bachelor's degree in economics from Paris IX Dauphine University.- Frederic Cren自2011年共同创立Inventiva以来一直担任我们的首席执行官，自2016年5月以来一直担任我们的董事会主席。此前，他曾于2010年至2012年担任制药公司雅培公司的研究总经理。在加入Abbott之前，Cren先生在Solvay Pharmaceuticals（一家制药公司）和Laboratoires Fournier SA（一家制药公司）担任过多个职位，直到该公司于2005年被Solvay收购。在Laboratories Fournier的职位包括:战略营销副总裁和美国运营副总裁，以及担任执行委员会成员。Solvay的职位包括:业务战略和投资组合主管和研究部高级副总裁，以及担任执行委员会成员。他的职业生涯始于任职Boston Consulting Group，在那里他曾任职（从1993年到2002年）。他在INSEAD获得工商管理硕士学位，在Johns Hopkins University获得国际关系硕士学位，在Paris IX Dauphine University获得经济学学士学位。
- Frederic Cren has served as our Chief Executive Officer since co-founding Inventiva in 2011 and as the chairman of our board of directors since May 2016. Previously, he served as the General Manager, Research of Abbott Laboratories, a pharmaceutical company, from 2010 until 2012. Prior to Abbott, Mr. Cren held a number of roles at Solvay Pharmaceuticals, a pharmaceutical company, and at Laboratoires Fournier SA, a pharmaceutical company, prior to its acquisition by Solvay in 2005. Positions at Laboratories Fournier included: Vice-President Strategic Marketing and Vice-President U.S. Operations, as well as serving as a member of the Executive Committee. Positions at Solvay included: Head of Business Strategy and Portfolio and Senior Vice-President of the Research Division, as well as serving as a member of the Executive Committee. Mr. Cren began his career with Boston Consulting Group, where he worked from 1993 to 2002. He received a master's degree in business administration from INSEAD, a master's degree in international relations from Johns Hopkins University and a bachelor's degree in economics from Paris IX Dauphine University.
- Pierre Broqua
Pierre Broqua自2011年共同创立Inventiva以来一直担任我们的首席科学官，并自2016年5月以来担任我们的副首席执行官兼董事会成员。此前，Broqua博士从2010年到2012年担任雅培公司的研究主管，从2007年到2010年担任Solvay Pharmaceuticals的神经科学主管。加入Solvay之前，Broqua从2002年到2005年担任Laboratoires Fournier SA研究项目主管。他在University of Paris Descartes获得药理学哲学博士学位，在Université；Pierre et Marie Curie，Paris获得化学与生物化学硕士学位。
Pierre Broqua has served as our Chief Scientific Officer since co-founding Inventiva in 2011 and as our Deputy Chief Executive Officer and a member of our board of directors since May 2016. Previously, Dr. Broqua served as a Head of Research for Abbott Laboratories from 2010 until 2012 and as Head of Neuroscience for Solvay Pharmaceuticals from 2007 to 2010. Prior to Solvay, Dr. Broqua was the Director of Research Project for Laboratoires Fournier SA from 2002 to 2005. He has a doctor of philosophy degree in pharmacology from the University of Paris Descartes and a master's degree in chemistry and biochemistry from Université Pierre et Marie Curie, Paris.- Pierre Broqua自2011年共同创立Inventiva以来一直担任我们的首席科学官，并自2016年5月以来担任我们的副首席执行官兼董事会成员。此前，Broqua博士从2010年到2012年担任雅培公司的研究主管，从2007年到2010年担任Solvay Pharmaceuticals的神经科学主管。加入Solvay之前，Broqua从2002年到2005年担任Laboratoires Fournier SA研究项目主管。他在University of Paris Descartes获得药理学哲学博士学位，在Université；Pierre et Marie Curie，Paris获得化学与生物化学硕士学位。
- Pierre Broqua has served as our Chief Scientific Officer since co-founding Inventiva in 2011 and as our Deputy Chief Executive Officer and a member of our board of directors since May 2016. Previously, Dr. Broqua served as a Head of Research for Abbott Laboratories from 2010 until 2012 and as Head of Neuroscience for Solvay Pharmaceuticals from 2007 to 2010. Prior to Solvay, Dr. Broqua was the Director of Research Project for Laboratoires Fournier SA from 2002 to 2005. He has a doctor of philosophy degree in pharmacology from the University of Paris Descartes and a master's degree in chemistry and biochemistry from Université Pierre et Marie Curie, Paris.
- Jean Volatier
Jean Volatier自2012年8月以来一直担任我们的首席财务官。此前，挥发先生曾于2011年1月至2011年10月担任i Care Environnement的高级顾问，i Care Environnement是一家咨询公司，2010年4月至2010年11月担任NaOS Group的临时首席财务官，NaOS Group是一家护肤公司，2010年4月至2010年11月担任Soufflet Group的首席财务官，一家农用工业公司，从2006年到2008年担任Laboratories Fournier国际运营财务总监，从1999年到2006年担任Urgo Soins&Sant&233；Laboratories（一家制药公司）控制主管，从1996年到1999年。他的职业生涯始于普华永道会计师事务所（PricewaterhouseCoopers），在那里他曾任职（1989年至1996年）。他持有Paris IX Dauphine University，PSL University的管理硕士学位，Mines-Paristech，PSL University、the DIPL&244；Me d’&233；Tudes Sup&233；Rieures Comptables and Financi&232；Res的企业社会责任执行专业硕士学位。
Jean Volatier has served as our Chief Financial Officer since August 2012. Previously, Mr. Volatier was a senior consultant for I Care Environnement, a consulting company, from January 2011 to October 2011 the interim Chief Financial Officer of the NAOS Group, a skin care company, from April 2010 to November 2010 the Chief Financial Officer of the Soufflet Group, an agro-industry company, from 2006 to 2008 the Financial Director - International Operations of Laboratories Fournier, from 1999 to 2006 and the Head of Controlling for URGO Soins & Santé Laboratories, a pharmaceutical company, from 1996 to 1999. Mr. Volatier began his career at PriceWaterhouseCoopers, where he worked from 1989 to 1996. He holds a master's degree in management from Paris IX Dauphine University, PSL University, an executive specialized master's degree in corporate social responsibility from MINES-ParisTech, PSL University, and the diplôme d'études supérieures comptables et financières.- Jean Volatier自2012年8月以来一直担任我们的首席财务官。此前，挥发先生曾于2011年1月至2011年10月担任i Care Environnement的高级顾问，i Care Environnement是一家咨询公司，2010年4月至2010年11月担任NaOS Group的临时首席财务官，NaOS Group是一家护肤公司，2010年4月至2010年11月担任Soufflet Group的首席财务官，一家农用工业公司，从2006年到2008年担任Laboratories Fournier国际运营财务总监，从1999年到2006年担任Urgo Soins&Sant&233；Laboratories（一家制药公司）控制主管，从1996年到1999年。他的职业生涯始于普华永道会计师事务所（PricewaterhouseCoopers），在那里他曾任职（1989年至1996年）。他持有Paris IX Dauphine University，PSL University的管理硕士学位，Mines-Paristech，PSL University、the DIPL&244；Me d’&233；Tudes Sup&233；Rieures Comptables and Financi&232；Res的企业社会责任执行专业硕士学位。
- Jean Volatier has served as our Chief Financial Officer since August 2012. Previously, Mr. Volatier was a senior consultant for I Care Environnement, a consulting company, from January 2011 to October 2011 the interim Chief Financial Officer of the NAOS Group, a skin care company, from April 2010 to November 2010 the Chief Financial Officer of the Soufflet Group, an agro-industry company, from 2006 to 2008 the Financial Director - International Operations of Laboratories Fournier, from 1999 to 2006 and the Head of Controlling for URGO Soins & Santé Laboratories, a pharmaceutical company, from 1996 to 1999. Mr. Volatier began his career at PriceWaterhouseCoopers, where he worked from 1989 to 1996. He holds a master's degree in management from Paris IX Dauphine University, PSL University, an executive specialized master's degree in corporate social responsibility from MINES-ParisTech, PSL University, and the diplôme d'études supérieures comptables et financières.
- Marie Paule Richard
Marie Paule Richard自2018年10月起担任Inventiva S.A.的首席医疗官。2014年至2018年，Richard博士担任Takeda Pharmaceutical company Ltd.收购的比利时生物技术公司TiGenix S.A.的首席医疗官。2010年至2012年，Richard博士还担任制药公司爱库里斯股份有限公司的首席医疗官，赛诺菲巴斯德公司临床开发副总裁，2001年至2007年，赛诺菲制药公司的疫苗部门在2000年至2001年期间担任葛兰素史克制药公司的全球高级集团总监，1993年至2000年期间担任安万特制药公司的临床开发总监。Richard博士获得南希大学医学院医学博士学位。
Marie Paule Richard has served as our Chief Medical Officer since October 2018. From 2014 to 2018 Dr. Richard was the Chief Medical Officer of TiGenix S.A., a Belgian biotechnology company that was acquired by Takeda Pharmaceutical Company Ltd. Dr. Richard also served as the Chief Medical Officer for AiCuris GmbH & Co., a pharmaceutical company, from 2010 to 2012 the Vice President of Clinical Development for Sanofi Pasteur, the vaccines division of the pharmaceutical company Sanofi S.A., from 2001 to 2007 the Global Senior Group Director for GlaxoSmithKline plc, a pharmaceutical company, from 2000 to 2001 and the Clinical Development Director for Aventis Pharma S.A. from 1993 to 2000. Dr. Richard received a doctor of medicine degree from the Medical School of Nancy University.- Marie Paule Richard自2018年10月起担任Inventiva S.A.的首席医疗官。2014年至2018年，Richard博士担任Takeda Pharmaceutical company Ltd.收购的比利时生物技术公司TiGenix S.A.的首席医疗官。2010年至2012年，Richard博士还担任制药公司爱库里斯股份有限公司的首席医疗官，赛诺菲巴斯德公司临床开发副总裁，2001年至2007年，赛诺菲制药公司的疫苗部门在2000年至2001年期间担任葛兰素史克制药公司的全球高级集团总监，1993年至2000年期间担任安万特制药公司的临床开发总监。Richard博士获得南希大学医学院医学博士学位。
- Marie Paule Richard has served as our Chief Medical Officer since October 2018. From 2014 to 2018 Dr. Richard was the Chief Medical Officer of TiGenix S.A., a Belgian biotechnology company that was acquired by Takeda Pharmaceutical Company Ltd. Dr. Richard also served as the Chief Medical Officer for AiCuris GmbH & Co., a pharmaceutical company, from 2010 to 2012 the Vice President of Clinical Development for Sanofi Pasteur, the vaccines division of the pharmaceutical company Sanofi S.A., from 2001 to 2007 the Global Senior Group Director for GlaxoSmithKline plc, a pharmaceutical company, from 2000 to 2001 and the Clinical Development Director for Aventis Pharma S.A. from 1993 to 2000. Dr. Richard received a doctor of medicine degree from the Medical School of Nancy University.